We are delighted to announce the appointment of Donmienne Leung, Director at AbbVie Ventures, to the Board of Directors at ThirtyFiveBio.

Donmienne is a strategic thinker and influential drug hunter with over 20 years of experience in drug discovery. At AbbVie Ventures, she combines deep scientific expertise with a passion for building long-term partnerships, leading early-stage investments in breakthrough science and pioneering platforms. Donmienne reflects our shared commitment to scientific excellence, long-term impact and meaningful innovation in pioneering the development of a gut epithelial shield to restore gut integrity and transform care for people with colitis.

‘We are thrilled to welcome Donmienne to our board,’ said James Westcott, ThirtyFiveBio CEO. ‘AbbVie’s strategic perspective and understanding of what it takes to bring transformative therapies to patients will be invaluable as we enter our next stage of growth towards the clinic.’

Donmienne’s appointment follows a period of significant momentum at ThirtyFiveBio, as we validate GPR35 antagonism in patient-derived models and move to late preclinical development of our candidate molecule.

With representation from AbbVie Ventures on our board and Annette Sterman Schwartz from AbbVie Inc. joining our scientific advisors, we are better positioned than ever to accelerate our work and bring new solutions to patients who need them.

We’re honoured to have Donmienne join us and look forward to the leadership and perspective she will bring as we continue our mission.